Optimal use of PCSK9-inhibitors according to the ESC/EAS Guidelines
City
Webinar
Type of event
virtual
Invitation
Dear Dr.
The Zurich Heart House would like to invite you to a special webinar on
Optimal use of PCSK9-inhibitors according to the ESC/EAS Guidelines
Date: Thursday, 05 November 2020 18:00 - 19:30
We are looking forward to meeting you during this webinar.
Dr. Ruth Amstein, FESC
Thomas F. Lüscher, FESC, FRCP
With an unrestricted educational grant from
Programme
| 18:00-18:05 | Introduction and moderation | Thomas F. Lüscher, London |
| 18:05-18:20 | What is a normal cholesterol? | Thomas F. Lüscher, London |
| 18:20-18:25 | Q & A | |
| 18:25-18:40 | Lessons from the ODYSSEY trial for the management of the hyperlipidaemic patient |
Andreas Zeiher, Frankfurt |
| 18:45-19:00 | Q & A | |
| 18:45-19:00 | Translating the 2019 ESC/EAS Dyslipidaemia guidelines into clinical practice: Lessons from the Da Vinci Registry |
Kausik Ray, London |
| 19:00-19:05 | Q & A | |
| 19:05-19:30 | Panel discussion |
Speakers
Faculty
Thomas F. Lüscher, Royal Brompton & Harefield Hospitals London, U.K.
Kausik Ray, Imperial College, U.K.
Andreas Zeiher, University Hospital Frankfurt, Germany.
Accreditation
This webinar has been approved by the Swiss Society of Cardiology with 2 credits 1 A
Sponsors